Journal of Renal Nutrition
Volume 11, Issue 3 , Pages 122-128 , July 2001

The emerging role of omega-3 polyunsaturated fatty acids in the management of patients with IgA nephropathy

References 

  1. GISSI-Prevenzione Investigators . Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–455
  2. Phillipson BE, Rothrock DW, Connor WE, et al.  Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med. 1985;312:1210–1216
  3. Donadio JV. Omega-3 polyunsaturated fatty acids: A potential new treatment of immune renal disease. Mayo Clin Proc. 1991;66:1018–1028
  4. De Caterina R, Endres S, Kristensen SD, et al.  n-3 fatty acids and renal disease. Am J Kidney Dis. 1994;24:397–414
  5. Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG. J Urol Nephrol. 1968;74:694–695
  6. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;245:709–727
  7. Julian BA, Waldo B, Rifai A, et al.  IgA nephropathy: The most common glomerulonephritis worldwide. Am J Med. 1988;84:129–132
  8. Donadio JV, Grande JP. Immunoglobulin A nephropathy: A clinical perspective. J Am Soc Nephrol. 1997;8:1324–1332
  9. Hood SA, Velosa JA, Holley KE, et al.  IgA-IgA nephropathy: Predictive indices of progressive disease. Clin Nephrol. 1981;16:55–62
  10. Droz D. Natural history of primary glomerulonephritis with mesangial deposits of IgA. Contrib Nephrol. 1976;2:150–157
  11. Radford MG, Donadio JV, Bergstralh EJ, et al.  Predicting renal outcomes in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207
  12. Ibels LS, Gyory AZ. IgA nephropathy: Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine. 1994;73:79–102
  13. Feehally J. Strategies for the management of IgA nephropathy. In: Annual Yearbook of Nephrology, Dialysis and Transplantation. Oxford, UK: Oxford University Press; 1994;p. 23–29
  14. Donadio JV. An overview of n-3 fatty acids in clinical renal diseases. In:  De Caterina R,  Endres S,  Kristensen SD, et al. editor. Current Topics in Cardiovascular Disease. Verona, Italy: Bi & Gi Publishers; 1993;p. 123–132
  15. Donadio JV, Bergstralh EJ, Offord KP, et al.  A controlled trial of fish oil in IgA nephropathy. N Engl J Med. 1994;331:1194–1199
  16. Donadio JV, Dart RA, Grande JP, et al.  The long-term outcome of patients with IgA nephropathy. J Am Soc Nephrol. 1999;10:1772–1777
  17. Donadio JV, Larson TS, Bergstralh EJ, et al.  A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001;12:791–799
  18. Holman RT. Essential fatty acid deficiency. Prog Chem Fats Other Lipids. 1971;9:275–348
  19. Holman RT. Biological activities and requirements for polyunsaturated fatty acids. Prog Chem Fats Other Lipids. 1971;9:607–682
  20. Crawford MA. Background to essential fatty acids and their prostanoid derivatives. Br Med Bull. 1983;39:210–213
  21. Holman RT. Nutritional and metabolic interrelationships between fatty acids. Fed Proc. 1964;23:1062–1067
  22. Holman RT. Control of polyunsaturated acids in tissue lipids. J Am Coll Nutr. 1986;5:183–211
  23. Lands WEM, Libelt B, Morris A, et al.  Maintenance of lower proportions of n-6 eicosanoid precursors in phospholipids of human plasma in response to added dietary n-3 fatty acids. Biochim Biophys Acta. 1992;1180:147–162
  24. Fischer S, Weber PC. Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature. 1984;307:165–168
  25. Fischer S, Weber PC. Thromboxane A3 (TxA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun. 1983;116:1091–1099
  26. Scharschmidt LA, Lianos E, Dunn MJ. Arachidonate metabolites and the control of glomerular function. Fed Proc. 1983;42:3058–3063
  27. Lee TH, Mencia-Huerta J-M, Corey EJ, et al.  Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest. 1984;74:1922–1933
  28. Terano T, Salmon JA, Moncada S. Antiinflammatory effects of eicosapentaenoic acid: Relevance to eicosanoid formation. In:  Hayaishi O,  Yamamoto S editor. Advances in Prostaglandin, Thromboxane, and Leukotriene Research. New York, NY: Raven; 1985;p. 253–255
  29. Holman RT, Johnson SB, Bibus D, et al.  Essential fatty acid deficiency profiles in idiopathic immunoglobulin A nephropathy. Am J Kidney Dis. 1994;23:648–654
  30. Grande JP, Walker HJ, Holub BJ, et al.  Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int. 2000;57:1027–1040
  31. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet. 1984;1:1017–1018
  32. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentaenoic acid (EPA): A two-year prospective trial. Clin Nephrol. 1989;31:128–131
  33. Pettersson EE, Rekola S, Berglund L, et al.  Treatment of IgA nephropathy with omega-3 polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clin Nephrol. 1994;41:183–190

☆ Address reprint requests to James V. Donadio, MD, Mayo Nephrology Collaborative Group, Mayo Clinic & Foundation, 200 First St, SW, MNCG Study Desk Eisenberg-S24, Rochester, MN 55905.

PII: S1051-2276(01)70024-6

Journal of Renal Nutrition
Volume 11, Issue 3 , Pages 122-128 , July 2001

Article Tools